Department of Biochemistry, Faculty of Medical Sciences, Urmia University of Medical Sciences, Urmia, Iran.
Asian Pac J Cancer Prev. 2022 Sep 1;23(9):2937-2942. doi: 10.31557/APJCP.2022.23.9.2937.
Multiple myeloma (MM) is known as an incurable heterogeneous plasma cell malignancy that presents with a variety of clinical manifestations. Inflammation plays an important role in this disease. Cytokines and Chemokines cause the progression of the disease. One of them is interleukin-1β (IL-1β), which may be involved in the pathogenesis of MM. Other markers such as calcium, albumin, creatinine, globulins, and total protein are also used to diagnose and prognosis patients. The main purpose of this study was to evaluate the serum level of IL-1β and various forms of calcium (total calcium, ionized calcium, and corrected calcium), albumin, creatinine, globulin, and total protein on stage-I of MM patients and healthy controls.
Serum samples from 30 stage-I MM patients and 30 healthy subjects as controls were examined in this study. The protein concentrations of serum IL-1β was assessed by enzyme-linked immunosorbent assay (ELISA), total calcium, albumin, creatinine, total protein, and globulin Measured by auto analyzer BT3000, an electrolyte analyzer was used to measure ionized calcium (Ca++) and a special equation was used to calculate the corrected calcium.
The mean level of IL-1β was significantly elevated in stage-I MM. The mean levels of IL-1β were 7.04±1.15 ng/ml in stage-I MM and 3.12± 0.90 ng/ml in controls (p<0.001). The mean levels of total calcium (total Ca) were 9.45±0.56 mg/dl in stage-I MM and 9.09±0.43mg/dl in controls (p=0.008). The mean levels of ionized calcium (Ca++) was 4.65±0.28mg/dl in stage-I MM and 4.75±0.33mg/dl in controls (p=0.2). The mean ratio of serum ionized calcium to total calcium (Ca++/ total Ca) was 0.49±0.054 in stage-I MM and 0.52±0.047 in controls (p=0.02). The mean ratio of serum ionized calcium to corrected calcium (Ca++/corrected Ca) was 0.42±0.033 in stage-I MM and the Mean ratio of serum ionized calcium to calcium total (Ca++/ total Ca) was 0.52±0.047 in controls, Comparison of the mean of the two groups shows a significant difference (p<0.001). The mean level of albumin was 1.72±0.35 g/dl in stage-I MM and4.32±0.41g/dl in controls (p<0.001). The mean level of total protein was 12.65±0.81g/dl in stage-I MM and 7.07±0.4 g/dl in controls (p<0.001). The mean level of globulin was 11.00±0.96 mg/dl in stage-I MM and 2.85±0.77 mg/dl in controls (p<0.001). The mean level of creatinine was 1.15±0.25 mg/dl in stage-I MM and 0.96±0.15 mg/dl in controls (p=0.001).
The results of the study indicate the possible involvement of IL-1β at stage-I MM and it can indicate the role of chemokines in the disease process, especially in the early stages. Changes in the chemical profiles mentioned can help in the diagnosis and prognosis of the disease.
多发性骨髓瘤(MM)是一种已知的不可治愈的异质性浆细胞恶性肿瘤,具有多种临床表现。炎症在这种疾病中起着重要作用。细胞因子和趋化因子导致疾病的进展。其中一种是白细胞介素-1β(IL-1β),它可能参与 MM 的发病机制。其他标志物,如钙、白蛋白、肌酐、球蛋白和总蛋白,也用于诊断和预测患者的预后。本研究的主要目的是评估 I 期 MM 患者和健康对照组的血清 IL-1β水平以及各种形式的钙(总钙、离子钙和校正钙)、白蛋白、肌酐、球蛋白和总蛋白。
本研究检查了 30 名 I 期 MM 患者和 30 名健康对照者的血清样本。通过酶联免疫吸附试验(ELISA)测定血清 IL-1β的蛋白浓度,用自动分析仪 BT3000 测定总钙、白蛋白、肌酐、总蛋白和球蛋白,用电解质分析仪测定离子钙(Ca++),并使用特殊方程计算校正钙。
I 期 MM 患者的 IL-1β 水平显著升高。I 期 MM 患者的 IL-1β 平均水平为 7.04±1.15ng/ml,对照组为 3.12±0.90ng/ml(p<0.001)。I 期 MM 患者的总钙(总 Ca)平均水平为 9.45±0.56mg/dl,对照组为 9.09±0.43mg/dl(p=0.008)。I 期 MM 患者的离子钙(Ca++)平均水平为 4.65±0.28mg/dl,对照组为 4.75±0.33mg/dl(p=0.2)。I 期 MM 患者血清离子钙与总钙的比值(Ca++/总 Ca)平均为 0.49±0.054,对照组为 0.52±0.047(p=0.02)。I 期 MM 患者血清离子钙与校正钙的比值(Ca++/校正 Ca)平均为 0.42±0.033,对照组为 0.52±0.047(两组均值比较有显著差异,p<0.001)。I 期 MM 患者白蛋白平均水平为 1.72±0.35g/dl,对照组为 4.32±0.41g/dl(p<0.001)。I 期 MM 患者总蛋白平均水平为 12.65±0.81g/dl,对照组为 7.07±0.4g/dl(p<0.001)。I 期 MM 患者球蛋白平均水平为 11.00±0.96mg/dl,对照组为 2.85±0.77mg/dl(p<0.001)。I 期 MM 患者肌酐平均水平为 1.15±0.25mg/dl,对照组为 0.96±0.15mg/dl(p=0.001)。
研究结果表明,IL-1β可能参与 I 期 MM,并提示趋化因子在疾病过程中的作用,特别是在早期阶段。上述化学特征的变化有助于疾病的诊断和预后。